BioCentury
ARTICLE | Financial News

Abingworth Management financial update

January 25, 2016 8:00 AM UTC

Avillion and SFJ finance late-stage trials and incur all of the clinical and regulatory costs and risk in exchange for a prenegotiated return once a therapeutic is approved. Abingworth co-founded both companies with Clarus Ventures.

Abingworth has made seven co-development investments through Avillion and SFJ, including an investment in the Phase III program for Lenvima lenvatinib from Eisai Co. Ltd. (Tokyo:4523, Tokyo, Japan). Lenvima is approved in the U.S., Europe and Japan to treat thyroid cancer, which Abingworth said led to a “high quality exit.” ...